{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:18Z","timestamp":1786981518567,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    As another part continue for our previous study, variable substituted pyrazoles bearing sulfamoylphenyl moiety were synthesized and screened against two cancer related human carbonic anhydrase (hCA) isoforms and acetazolamide (AAZ) used as a reference standard. Some compounds as\n                    <jats:bold>4e<\/jats:bold>\n                    and\n                    <jats:bold>6c<\/jats:bold>\n                    manifested a promising inhibitory activity against both isoforms (K\n                    <jats:sub>I<\/jats:sub>\n                    \u2009=\u20090.072, 0.081 and 0.073, 0.095 \u00b5M), respectively. While others as\n                    <jats:bold>4a<\/jats:bold>\n                    and\n                    <jats:bold>5e<\/jats:bold>\n                    showed inhibitory activity against hCA IX only (K\n                    <jats:sub>I<\/jats:sub>\n                    \u2009=\u20090.062, 0.04 \u00b5M) or against hCA XII only as compound\n                    <jats:bold>5b<\/jats:bold>\n                    (K\n                    <jats:sub>I<\/jats:sub>\n                    \u2009=\u20090.106 \u00b5M) compared to AAZ (K\n                    <jats:sub>I<\/jats:sub>\n                    \u2009=\u20090.065, 0.046 \u00b5M), respectively. Also, the anticancer efficacy against 60 cancer cell lines for the target compounds was assessed, and the most promising ones were\n                    <jats:bold>4d<\/jats:bold>\n                    and\n                    <jats:bold>5a-d<\/jats:bold>\n                    . Further investigation of the anticancer activity of\n                    <jats:bold>5b<\/jats:bold>\n                    on MCF-7 cell line explored (IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u20095.21 \u00b5M) compared to doxorubicin (IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u200911.58 \u00b5M). Moreover, compound\n                    <jats:bold>5b<\/jats:bold>\n                    was exposed to cell cycle analysis and apoptotic assay on MCF-7 breast cancer cell line under both normal and hypoxic conditions at its IC\n                    <jats:sub>50<\/jats:sub>\n                    concentration with elevation of total apoptotic cells % in MCF-7 relative to the control cells; respectively. Finally, molecular modelling simulations rationalized the in vitro testing results.\n                  <\/jats:p>","DOI":"10.1007\/s11030-024-11023-3","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T13:18:19Z","timestamp":1731331099000},"page":"4705-4725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Insight on novel sulfamoylphenyl pyrazole derivatives as anticancer carbonic anhydrase inhibitors"],"prefix":"10.1007","volume":"29","author":[{"given":"Rehab F.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa R.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagwa M.","family":"Abdelgawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany","family":"Belal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem I.","family":"Alsantali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona F.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"11023_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.bmc.2012.04.044","volume":"21","author":"M Imtaiyaz Hassan","year":"2013","unstructured":"Imtaiyaz Hassan M, Shajee B, Waheed A, Ahmad F, Sly WS (2013) Structure, function and applications of carbonic anhydrase isozymes. Bioorg Med Chem 21:1570\u20131582. https:\/\/doi.org\/10.1016\/j.bmc.2012.04.044","journal-title":"Bioorg Med Chem"},{"key":"11023_CR2","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1021\/cr200176r","volume":"112","author":"V Alterio","year":"2012","unstructured":"Alterio V, Di Fiore A, D\u2019Ambrosio K, Supuran CT, De Simone G (2012) Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms? Chem Rev 112:4421\u20134468. https:\/\/doi.org\/10.1021\/cr200176r","journal-title":"Chem Rev"},{"key":"11023_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1517\/13543776.2013.798648","volume":"23","author":"SM Monti","year":"2013","unstructured":"Monti SM, Supuran CT, De Simone G (2013) Anticancer carbonic anhydrase inhibitors: a patent review (2008\u20132013). Expert Opin Ther Pat 23:737\u2013749. https:\/\/doi.org\/10.1517\/13543776.2013.798648","journal-title":"Expert Opin Ther Pat"},{"key":"11023_CR4","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1080\/14756366.2019.1664501","volume":"34","author":"S Akocak","year":"2019","unstructured":"Akocak S, Supuran CT (2019) Activation of \u03b1-, \u03b2-, \u03b3-\u03b4-, \u03b6-and \u03b7-class of carbonic anhydrases with amines and amino acids: a review. J Enzyme Inhib Med Chem 34:1652\u20131659. https:\/\/doi.org\/10.1080\/14756366.2019.1664501","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11023_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12915-021-01039-8","volume":"19","author":"Y Hirakawa","year":"2021","unstructured":"Hirakawa Y, Senda M, Fukuda K, Yu HY, Ishida M, Taira M, Kinbara K, Senda T (2021) Characterization of a novel type of carbonic anhydrase that acts without metal cofactors. BMC Biol 19:1\u201315. https:\/\/doi.org\/10.1186\/s12915-021-01039-8","journal-title":"BMC Biol"},{"key":"11023_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"CT Supuran","year":"2008","unstructured":"Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7:168\u2013181. https:\/\/doi.org\/10.1038\/nrd2467","journal-title":"Nat Rev Drug Discov"},{"key":"11023_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2018.04.016","volume":"152","author":"HS Ibrahim","year":"2018","unstructured":"Ibrahim HS, Allam HA, Mahmoud WR, Bonardi A, Nocentini A, Gratteri P, Ibrahim ES, Abdel-Aziz HA, Supuran CT (2018) Dual-tail arylsulfone-based benzenesulfonamides differently match the hydrophobic and hydrophilic halves of human carbonic anhydrases active sites: selective inhibitors for the tumor-associated hCA IX isoform. Eur J Med Chem 152:1\u20139. https:\/\/doi.org\/10.1016\/j.ejmech.2018.04.016","journal-title":"Eur J Med Chem"},{"key":"11023_CR8","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.bmc.2016.01.038","volume":"24","author":"S Carradori","year":"2016","unstructured":"Carradori S, Secci D, De Monte C, Mollica A, Ceruso M, Akdemir A, Sobolev AP, Codispoti R, De Cosmi F, Guglielmi P (2016) A novel library of saccharin and acesulfame derivatives as potent and selective inhibitors of carbonic anhydrase IX and XII isoforms. Bioorg Med Chem 24:1095\u20131105","journal-title":"Bioorg Med Chem"},{"key":"11023_CR9","doi-asserted-by":"publisher","first-page":"7608","DOI":"10.1073\/pnas.95.13.7608","volume":"95","author":"\u00d6 T\u00fcreci","year":"1998","unstructured":"T\u00fcreci \u00d6, Sahin U, Vollmar E, Siemer S, G\u00f6ttert E, Seitz G, Parkkila AK, Shah GN, Grubb JH, Pfreundschuh M, Sly WS (1998) Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA 95:7608\u20137613. https:\/\/doi.org\/10.1073\/pnas.95.13.7608","journal-title":"Proc Natl Acad Sci USA"},{"key":"11023_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.gene.2017.04.027.Carbonic","volume":"623","author":"A Waheed","year":"2017","unstructured":"Waheed A, Sly WS, Doisy EA (2017) Carbonic anhydrase XII functions in health and disease. Gene 623:33\u201340. https:\/\/doi.org\/10.1016\/j.gene.2017.04.027.Carbonic","journal-title":"Gene"},{"key":"11023_CR11","doi-asserted-by":"publisher","first-page":"103514","DOI":"10.1016\/j.bioorg.2019.103514","volume":"95","author":"RF George","year":"2020","unstructured":"George RF, Said MF, Bua S, Supuran CT (2020) Synthesis and selective inhibitory effects of some 2-oxindole benzenesulfonamide conjugates on human carbonic anhydrase isoforms CA I, CA II, CA IX and CAXII. Bioorg Chem 95:103514. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103514","journal-title":"Bioorg Chem"},{"key":"11023_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2174\/138955706777934946","volume":"6","author":"J-Y Winum","year":"2006","unstructured":"Winum J-Y, Scozzafava A, Montero J-L, Supuran C (2006) New zinc binding motifs in the design of selective carbonic anhydrase inhibitors. Mini-Rev Med Chem 6:921\u2013936. https:\/\/doi.org\/10.2174\/138955706777934946","journal-title":"Mini-Rev Med Chem"},{"key":"11023_CR13","doi-asserted-by":"publisher","first-page":"190407","DOI":"10.1098\/rsos.190407","volume":"6","author":"DK Park","year":"2019","unstructured":"Park DK, Lee MS (2019) Kinetic study of catalytic CO2 hydration by metal-substituted biomimetic carbonic anhydrase model complexes. R Soc Open Sci 6:190407\u2013190416. https:\/\/doi.org\/10.1098\/rsos.190407","journal-title":"R Soc Open Sci"},{"key":"11023_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0163-7258(96)00198-2","volume":"74","author":"S Lindskog","year":"1997","unstructured":"Lindskog S (1997) Structure and mechanism of carbonic Anhydrase. Pharmacol Ther 74:1\u201320. https:\/\/doi.org\/10.1016\/s0163-7258(96)00198-2","journal-title":"Pharmacol Ther"},{"key":"11023_CR15","doi-asserted-by":"publisher","first-page":"103222","DOI":"10.1016\/j.bioorg.2019.103222","volume":"92","author":"C Yamali","year":"2019","unstructured":"Yamali C, Gul HI, Ece A, Bua S, Angeli A, Sakagami H, Sahin E, Supuran CT (2019) Synthesis, biological evaluation and in silico modelling studies of 1,3,5-trisubstituted pyrazoles carrying benzenesulfonamide as potential anticancer agents and selective cancer-associated hCA IX isoenzyme inhibitors. Bioorg Chem 92:103222. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103222","journal-title":"Bioorg Chem"},{"key":"11023_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejmech.2014.02.023","volume":"76","author":"P Khloya","year":"2014","unstructured":"Khloya P, Celik G, Sitaram, Vullo D, Supuran CT, Sharma PK (2014) 4-Functionalized 1,3-diarylpyrazoles bearing benzenesulfonamide moiety as selective potent inhibitors of the tumor associated carbonic anhydrase isoforms IX and XII. Eur J Med Chem 76:284\u2013290. https:\/\/doi.org\/10.1016\/j.ejmech.2014.02.023","journal-title":"Eur J Med Chem"},{"key":"11023_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.bioorg.2018.01.021","volume":"77","author":"HI Gul","year":"2018","unstructured":"Gul HI, Yamali C, Sakagami H, Angeli A, Leitans J, Kazaks A, Tars K, Ozgun DO, Supuran CT (2018) New anticancer drug candidates sulfonamides as selective hCA IX or hCA XII inhibitors. Bioorg Chem 77:411\u2013419. https:\/\/doi.org\/10.1016\/j.bioorg.2018.01.021","journal-title":"Bioorg Chem"},{"key":"11023_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ejmech.2015.09.021","volume":"103","author":"HS Ibrahim","year":"2015","unstructured":"Ibrahim HS, Abou-Seri SM, Tanc M, Elaasser MM, Abdel-Aziz HA, Supuran CT (2015) Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII. Eur J Med Chem 103:583\u2013593. https:\/\/doi.org\/10.1016\/j.ejmech.2015.09.021","journal-title":"Eur J Med Chem"},{"key":"11023_CR19","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.bmc.2016.04.052","volume":"24","author":"N Chandak","year":"2016","unstructured":"Chandak N, Ceruso M, Supuran CT, Sharma PK (2016) Novel sulfonamide bearing coumarin scaffolds as selective inhibitors of tumor associated carbonic anhydrase isoforms IX and XII. Bioorg Med Chem 24:2882\u20132886. https:\/\/doi.org\/10.1016\/j.bmc.2016.04.052","journal-title":"Bioorg Med Chem"},{"key":"11023_CR20","doi-asserted-by":"publisher","first-page":"115805","DOI":"10.1016\/j.ejmech.2023.115805","volume":"261","author":"RF Ahmed","year":"2023","unstructured":"Ahmed RF, Mahmoud WR, Abdelgawad NM, Fouad MA, Said MF (2023) Exploring novel anticancer pyrazole benzenesulfonamides featuring tail approach strategy as carbonic anhydrase inhibitors. Eur J Med Chem 261:115805. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115805","journal-title":"Eur J Med Chem"},{"key":"11023_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules27144610","volume":"27","author":"A Gumus","year":"2022","unstructured":"Gumus A, Bozdag M, Akdemir A, Angeli A, Selleri S, Carta F, Supuran CT (2022) Thiosemicarbazide-substituted coumarins as selective inhibitors of the tumor associated human carbonic anhydrases IX and XII. Molecules 27:1\u201314. https:\/\/doi.org\/10.3390\/molecules27144610","journal-title":"Molecules"},{"key":"11023_CR22","doi-asserted-by":"publisher","first-page":"131145","DOI":"10.1016\/j.molstruc.2021.131145","volume":"1246","author":"M Abas","year":"2021","unstructured":"Abas M, Bahadur A, Ashraf Z, Iqbal S, Rajoka MSR, Rashid SG, Jabeen E, Iqbal Z, Abbas Q, Bais A, Hassan M, Liu G, Feng K, Lee SH, Nawaz M, Qayyum MA (2021) Designing novel anticancer sulfonamide based 2,5-disubstituted-1,3,4-thiadiazole derivatives as potential carbonic anhydrase inhibitor. J Mol Struct 1246:131145. https:\/\/doi.org\/10.1016\/j.molstruc.2021.131145","journal-title":"J Mol Struct"},{"key":"11023_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.21608\/ejchem.2015.1011","volume":"58","author":"AMF Fahmy","year":"2015","unstructured":"Fahmy AMF, Abdel-Hamid HA, Megally Abdo NY (2015) Uses of isothiocyanate as building block in syntheses of triazole, thiadiazole, quinazoline, and pyrimidine systems of agrochemical and biological activities. Egypt J Chem 58:645\u2013657","journal-title":"Egypt J Chem"},{"key":"11023_CR24","doi-asserted-by":"publisher","first-page":"13506","DOI":"10.1002\/slct.202103636","volume":"6","author":"L Urbelyt\u0117","year":"2021","unstructured":"Urbelyt\u0117 L, Bagdonas M, Grybait\u0117 B, Vaickelionien\u0117 R, Mickevi\u010di\u016bt\u0117 A, Michailovien\u0117 V, Matulis D, Mickevi\u010dius V, Zubrien\u0117 A (2021) Design and synthesis of hydrazone-bearing benzenesulfonamides as carbonic anhydrase VB inhibitors. ChemistrySelect 6:13506\u201313513. https:\/\/doi.org\/10.1002\/slct.202103636","journal-title":"ChemistrySelect"},{"key":"11023_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/cber.19270600118","volume":"60","author":"A Vilsmeier","year":"1927","unstructured":"Vilsmeier A, Haack A (1927) A Vilsmeier und A Haack: aber die Einwirkung von Halogenphosphor auf Alkyl-formanilide. Eine neue Methode zur Darstellung sekundarer und tertiarer p-Alkylamino-benzaldehyde. Ber Dtsch Chem Ges 60:119\u2013122. https:\/\/doi.org\/10.1002\/cber.19270600118","journal-title":"Ber Dtsch Chem Ges"},{"key":"11023_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6393428","volume":"2020","author":"M Assali","year":"2020","unstructured":"Assali M, Abualhasan M, Sawaftah H, Hawash M, Mousa A (2020) Synthesis, biological activity, and molecular modeling studies of pyrazole and triazole derivatives as selective COX-2 inhibitors. J Chem 2020:1\u201314. https:\/\/doi.org\/10.1155\/2020\/6393428","journal-title":"J Chem"},{"key":"11023_CR27","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/s0021-9258(18)62326-9","volume":"246","author":"RG Khalifah","year":"1971","unstructured":"Khalifah RG (1971) The carbon dioxide hydration activity of carbonic anhydrase. J Biol Chem 246:2561\u20132573. https:\/\/doi.org\/10.1016\/s0021-9258(18)62326-9","journal-title":"J Biol Chem"},{"key":"11023_CR28","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/J.EJMECH.2011.01.060","volume":"46","author":"PK Sharma","year":"2011","unstructured":"Sharma PK, Chandak N, Kumar P, Sharma C, Aneja KR (2011) Synthesis and biological evaluation of some 4-functionalized-pyrazoles as antimicrobial agents. Eur J Med Chem 46:1425\u20131432. https:\/\/doi.org\/10.1016\/J.EJMECH.2011.01.060","journal-title":"Eur J Med Chem"},{"key":"11023_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3791\/2597","volume":"50","author":"AM Rieger","year":"2011","unstructured":"Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR (2011) Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death. J Vis Exp 50:1\u20134. https:\/\/doi.org\/10.3791\/2597","journal-title":"J Vis Exp"},{"key":"11023_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1677\/erc.0.0060017","volume":"6","author":"W Gorczyca","year":"1999","unstructured":"Gorczyca W (1999) Cytometric analyses to distinguish death processes. Endocr Relat Cancer 6:17\u201319. https:\/\/doi.org\/10.1677\/erc.0.0060017","journal-title":"Endocr Relat Cancer"},{"key":"11023_CR31","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1021\/acs.jmedchem.5b01343","volume":"58","author":"J Leitans","year":"2015","unstructured":"Leitans J, Kazaks A, Balode A, Ivanova J, Zalubovskis R, Supuran CT, Tars K (2015) Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX. J Med Chem 58:9004\u20139009. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01343","journal-title":"J Med Chem"},{"key":"11023_CR32","doi-asserted-by":"publisher","first-page":"9545","DOI":"10.1073\/pnas.161301298","volume":"98","author":"DA Whittington","year":"2001","unstructured":"Whittington DA, Waheed A, Ulmasov B, Shah GN, Grubb JH, Sly WS, Christianson DW (2001) Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. PNAS 98:9545\u20139550. https:\/\/doi.org\/10.1073\/pnas.161301298","journal-title":"PNAS"},{"key":"11023_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1021\/ci800305f","volume":"49","author":"T Sander","year":"2009","unstructured":"Sander T, Freyss J, Von Korff M, Reich JR, Rufener C (2009) OSIRIS, an entirely in-house developed drug discovery informatics system. J Chem Inf Model 49:232\u2013246. https:\/\/doi.org\/10.1021\/ci800305f","journal-title":"J Chem Inf Model"},{"key":"11023_CR34","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/14756366.2016.1241781","volume":"32","author":"Y Entezari Heravi","year":"2017","unstructured":"Entezari Heravi Y, Sereshti H, Saboury AA, Ghasemi J, Amirmostofian M, Supuran CT (2017) 3D QSAR studies, pharmacophore modeling, and virtual screening of diarylpyrazole\u2013benzenesulfonamide derivatives as a template to obtain new inhibitors, using human carbonic anhydrase II as a model protein. J Enzyme Inhib Med Chem 32:688\u2013700. https:\/\/doi.org\/10.1080\/14756366.2016.1241781","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11023_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1021\/bi00853a037","volume":"6","author":"Y Pocker","year":"1967","unstructured":"Pocker Y, Meany JE (1967) The catalytic versatility of erythrocyte carbonic anhydrase: II\u2014Kinetic studies of the enzyme-catalyzed hydration of pyridine aldehydes. Biochemistry 6:239\u2013246. https:\/\/doi.org\/10.1021\/bi00853a037","journal-title":"Biochemistry"},{"key":"11023_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph13050094","volume":"13","author":"N Ur Rehman","year":"2020","unstructured":"Ur Rehman N, Ahsan Halim S, Khan M, Hussain H, Yar Khan H, Khan A, Abbas G, Rafiq K, Al-Harrasi A (2020) Antiproliferative and carbonic anhydrase II inhibitory potential of chemical constituents from lycium shawii and aloe vera: evidence from in silico target fishing and in vitro testing. Pharmaceuticals 13:1\u201318. https:\/\/doi.org\/10.3390\/ph13050094","journal-title":"Pharmaceuticals"},{"key":"11023_CR37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","volume":"83","author":"A Monks","year":"1991","unstructured":"Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757\u2013766. https:\/\/doi.org\/10.1093\/jnci\/83.11.757","journal-title":"J Natl Cancer Inst"},{"key":"11023_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ddr.430340203","volume":"34","author":"MR Boyd","year":"1995","unstructured":"Boyd MR, Paull KD (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91\u2013109. https:\/\/doi.org\/10.1002\/ddr.430340203","journal-title":"Drug Dev Res"},{"key":"11023_CR39","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"P Skehan","year":"1990","unstructured":"Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107\u20131112. https:\/\/doi.org\/10.1093\/jnci\/82.13.1107","journal-title":"J Natl Cancer Inst"},{"key":"11023_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.vascn.2013.09.003","volume":"69","author":"M Boncler","year":"2014","unstructured":"Boncler M, R\u00f3zalski M, Krajewska U, Podswdek A, Watala C (2014) Comparison of PrestoBlue and MTT assays of cellular viability in the assessment of anti-proliferative effects of plant extracts on human endothelial cells. J Pharmacol Toxicol Methods 69:9\u201316. https:\/\/doi.org\/10.1016\/j.vascn.2013.09.003","journal-title":"J Pharmacol Toxicol Methods"},{"key":"11023_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cyto.a.10117","volume":"57","author":"D Tao","year":"2004","unstructured":"Tao D, Wu J, Feng Y, Qin J, Hu J, Gong J (2004) New method for the analysis of cell cycle-specific apoptosis. Cytometry A 57:70\u201374. https:\/\/doi.org\/10.1002\/cyto.a.10117","journal-title":"Cytometry A"},{"key":"11023_CR42","doi-asserted-by":"publisher","first-page":"105421","DOI":"10.1016\/j.bioorg.2021.105421","volume":"117","author":"M El-Hussieny","year":"2021","unstructured":"El-Hussieny M, El-Sayed NF, Fouad MA, Ewies EF (2021) Synthesis, biological evaluation and molecular docking of new sulfonamide-based indolinone derivatives as multitargeted kinase inhibitors against leukemia. Bioorg Chem 117:105421. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105421","journal-title":"Bioorg Chem"},{"key":"11023_CR43","doi-asserted-by":"publisher","first-page":"104985","DOI":"10.1016\/j.bioorg.2021.104985","volume":"112","author":"MA Fouad","year":"2021","unstructured":"Fouad MA, Zaki MY, Lotfy RA, Mahmoud WR (2021) Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma. Bioorg Chem 112:104985. https:\/\/doi.org\/10.1016\/j.bioorg.2021.104985","journal-title":"Bioorg Chem"},{"key":"11023_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ejmech.2019.07.029","volume":"180","author":"EF Ewies","year":"2019","unstructured":"Ewies EF, El-Hussieny M, El-Sayed NF, Fouad MA (2019) Design, synthesis and biological evaluation of novel \u03b1-aminophosphonate oxadiazoles via optimized iron triflate catalyzed reaction as apoptotic inducers. Eur J Med Chem 180:310\u2013320. https:\/\/doi.org\/10.1016\/j.ejmech.2019.07.029","journal-title":"Eur J Med Chem"},{"key":"11023_CR45","doi-asserted-by":"publisher","first-page":"113389","DOI":"10.1016\/j.ejmech.2021.113389","volume":"218","author":"GS Hassan","year":"2021","unstructured":"Hassan GS, Georgey HH, Mohammed EZ, George RF, Mahmoud WR, Omar FA (2021) Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors. Eur J Med Chem 218:113389. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113389","journal-title":"Eur J Med Chem"},{"key":"11023_CR46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5395\/rde.2015.40.2.172","volume":"40","author":"H-Y Kim","year":"2015","unstructured":"Kim H-Y (2015) Statistical notes for clinical researchers: post-hoc multiple comparisons. Restor Dent Endod 40:172\u2013176. https:\/\/doi.org\/10.5395\/rde.2015.40.2.172","journal-title":"Restor Dent Endod"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11023-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-11023-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11023-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:03:10Z","timestamp":1758600190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-11023-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["11023"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-11023-3","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"1 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}